HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
KIF11
kinesin family member 11
Chromosome 10 Β· 10q23.33
NCBI Gene: 3832Ensembl: ENSG00000138160.8HGNC: HGNC:6388UniProt: P52732
313PubMed Papers
21Diseases
4Drugs
181Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
Clinical TrialsOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
spindlecytosolmicrotubulemembranemicrocephaly with or without chorioretinopathy, lymphedema, or intellectual disabilityRetinal dystrophyneurodegenerative diseasegenetic disorder
✦AI Summary

KIF11 is a plus-end-directed microtubule motor protein essential for establishing bipolar mitotic spindles and chromosome 10 during cell division 12. In non-mitotic cells, KIF11 mediates secretory protein transport from the Golgi complex to the cell surface 3. Beyond mitosis, KIF11 localizes to the photoreceptor cilium transition zone, where UFMylation at lysine 953 stabilizes the protein and maintains photoreceptor cilium integrity and retinal homeostasis 4. KIF11 is critical for spindle bipolarization in human oocytes, with mutations identified in infertile patients with oocyte defects 5. KIF11 dysfunction underlies several diseases. Pathogenic KIF11 mutations cause familial exudative vitreoretinopathy (FEVR), a retinal vascular disease 6, and are associated with microcephaly and developmental disorders. Dysregulation drives cancer progression: KIF11 is significantly upregulated in endometrial cancer, esophageal squamous cell carcinoma, and pancreatic ductal adenocarcinoma, correlating with poor prognosis and enhanced tumor proliferation, migration, and chemoresistance 789. KIF11 inhibitors have entered clinical trials as promising cancer therapeutics 1011, with knockdown inducing G2/M phase arrest and apoptosis in cancer cells.

Sources cited
1
KIF11 required for establishing bipolar spindle and chromosome congression during mitosis
PMID: 19001501
2
KIF11 required for establishing bipolar spindle and chromosome congression during mitosis
PMID: 37728657
3
KIF11 required in non-mitotic cells for transport of secretory proteins from Golgi to cell surface
PMID: 23857769
4
KIF11 localizes at photoreceptor cilium transition zone; UFMylation at K953 stabilizes KIF11 and maintains cilium integrity and retinal homeostasis
PMID: 38666385
5
KIF11 has essential role in spindle bipolarization in human oocytes; mutations identified in infertile patients
PMID: 39172836
6
KIF11 mutations cause familial exudative vitreoretinopathy
PMID: 34860240
7
KIF11 is highly expressed in endometrial cancer, associated with tumor grade, stage, and poor survival; knockdown inhibits proliferation, migration, and invasion, induces G2/M arrest and apoptosis
PMID: 39806429
8
KIF11 is upregulated in esophageal squamous cell carcinoma and promotes tumor proliferation and migration; negatively correlates with CD8+ T cell infiltration
PMID: 39966857
9
KIF11 interacts with TACC3 in pancreatic cancer; KIF11 knockdown causes abnormal spindle formation and increases chemosensitivity to gemcitabine
PMID: 38012214
10
KIF11 inhibitors have entered Phase I and II clinical trials for cancer treatment
PMID: 22825217
11
KIF11 is upregulated in various cancers and promotes cancer progression; functions as potential prognostic biomarker and therapeutic target
PMID: 38672404
Disease Associationsβ“˜21
microcephaly with or without chorioretinopathy, lymphedema, or intellectual disabilityOpen Targets
0.82Strong
Retinal dystrophyOpen Targets
0.51Moderate
neurodegenerative diseaseOpen Targets
0.48Moderate
genetic disorderOpen Targets
0.47Moderate
type 2 diabetes mellitusOpen Targets
0.45Moderate
microcephalyOpen Targets
0.41Moderate
asthmaOpen Targets
0.40Weak
childhood onset asthmaOpen Targets
0.35Weak
Neurodevelopmental delayOpen Targets
0.34Weak
retinitis pigmentosaOpen Targets
0.34Weak
ulcerative colitisOpen Targets
0.34Weak
microcephaly and chorioretinopathy 1Open Targets
0.33Weak
syndromic retinitis pigmentosaOpen Targets
0.33Weak
inflammatory bowel diseaseOpen Targets
0.31Weak
Left bundle branch blockOpen Targets
0.29Weak
major salivary gland cancerOpen Targets
0.29Weak
Neurodevelopmental disorderOpen Targets
0.27Weak
lymphedemaOpen Targets
0.26Weak
Retinal dysplasiaOpen Targets
0.26Weak
diabetes mellitusOpen Targets
0.22Weak
Microcephaly with or without chorioretinopathy, lymphedema, or impaired intellectual developmentUniProt
Pathogenic Variants181
NM_004523.4(KIF11):c.2178_2181del (p.Met726fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 726
NM_004523.4(KIF11):c.157C>T (p.Arg53Ter)Pathogenic
not provided|Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability
β˜…β˜…β˜†β˜†2025β†’ Residue 53
NM_004523.4(KIF11):c.308+1G>APathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025
NM_004523.4(KIF11):c.2922G>A (p.Pro974=)Pathogenic
not specified|Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided|Malignant tumor of urinary bladder
β˜…β˜…β˜†β˜†2025β†’ Residue 974
NM_004523.4(KIF11):c.139C>T (p.Arg47Ter)Pathogenic
not provided|Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|Retinal dystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 47
NM_004523.4(KIF11):c.2T>C (p.Met1Thr)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 1
NM_004523.4(KIF11):c.388-1G>CPathogenic
not provided|KIF11-related disorder
β˜…β˜…β˜†β˜†2025
NM_004523.4(KIF11):c.2402_2403del (p.His800_Ser801insTer)Pathogenic
not provided|Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability
β˜…β˜…β˜†β˜†2025β†’ Residue 800
NM_004523.4(KIF11):c.436A>T (p.Lys146Ter)Pathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 146
NM_004523.4(KIF11):c.2514_2518del (p.Asn838fs)Pathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|Microcephaly and chorioretinopathy 1|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 838
NM_004523.4(KIF11):c.790-1G>TPathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|Microcephaly with or without chorioretinopathy, lymphedema or intellectual disability (MCLID)|not provided
β˜…β˜…β˜†β˜†2024
NM_004523.4(KIF11):c.247C>T (p.Arg83Ter)Pathogenic
not provided|Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability
β˜…β˜…β˜†β˜†2024β†’ Residue 83
NM_004523.4(KIF11):c.439del (p.Thr148fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 148
NM_004523.4(KIF11):c.2263C>T (p.Gln755Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 755
NM_004523.4(KIF11):c.2697_2700del (p.Asn899fs)Pathogenic
Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 899
NM_004523.4(KIF11):c.2230C>T (p.Gln744Ter)Pathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 744
NM_004523.4(KIF11):c.2158C>T (p.Gln720Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 720
NM_004523.4(KIF11):c.2304_2305del (p.His768fs)Pathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 768
NM_004523.4(KIF11):c.2161-1G>APathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability|not provided
β˜…β˜…β˜†β˜†2023
NM_004523.4(KIF11):c.2312_2313del (p.Lys771fs)Pathogenic
Microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability
β˜…β˜…β˜†β˜†2023β†’ Residue 771
View on ClinVar β†—
Drug Targets4
AZD-4877Phase II
Kinesin-like protein 1 inhibitor
acute myeloid leukemia by FAB classification
FILANESIBPhase II
Kinesin-like protein 1 inhibitor
multiple myeloma
ISPINESIBPhase II
Kinesin-like protein 1 inhibitor
head and neck malignant neoplasia
LITRONESIBPhase II
Kinesin-like protein 1 inhibitor
acute myeloid leukemia by FAB classification
Related Genes
TPX2Protein interaction100%TUBA1BProtein interaction100%BUB1BProtein interaction100%FOXM1Protein interaction100%PCLAFProtein interaction100%ARHGAP11AProtein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
30%
Lung
3%
Heart
2%
Liver
2%
Ovary
1%
Gene Interaction Network
Click a node to explore
KIF11TPX2TUBA1BBUB1BFOXM1PCLAFARHGAP11A
PROTEIN STRUCTURE
Preparing viewer…
PDB6TIW Β· 1.09 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.18Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.07 [0.03–0.18]
RankingsWhere KIF11 stands among ~20K protein-coding genes
  • #1,085of 20,598
    Most Researched313 Β· top 10%
  • #392of 5,498
    Most Pathogenic Variants181 Β· top 10%
  • #359of 17,882
    Most Constrained (LOEUF)0.18 Β· top 5%
Genes detectedKIF11
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer.
PMID: 39806429
J Transl Med Β· 2025
1.00
2
KIF11 UFMylation Maintains Photoreceptor Cilium Integrity and Retinal Homeostasis.
PMID: 38666385
Adv Sci (Weinh) Β· 2024
0.90
3
Mechanisms of minor pole-mediated spindle bipolarization in human oocytes.
PMID: 39172836
Science Β· 2024
0.80
4
Ocular Features and Mutation Spectrum of Patients With Familial Exudative Vitreoretinopathy.
PMID: 34860240
Invest Ophthalmol Vis Sci Β· 2021
0.70
5
Mitotic Functions and Characters of KIF11 in Cancers.
PMID: 38672404
Biomolecules Β· 2024
0.60